Advances in Stem Cell Therapy for Autoimmune Diseases 2026

If you want the short answer: autologous HSCT still has the strongest long-term results, especially in multiple sclerosis and systemic sclerosis. MSC therapy looks more mixed but shows promise in Crohn’s disease, lupus, and some rheumatoid arthritis studies. Exosomes are still early.

Here’s the plain-English version:

• HSCT has the best long-term track record for severe autoimmune disease
• In MS, studies report NEDA rates from 66% to 93%
• In systemic sclerosis, 5-year progression-free survival is about 70% to 74%
• Reduced-intensity conditioning may lower some treatment harm while keeping outcomes strong
• MSC therapy is usually easier on patients than HSCT, but the long-term data are less even across diseases
• Cord tissue and placental tissue matter mainly as MSC sources
• Cord blood matters more for hematopoietic stem cells tied to immune reset research
• Exosome therapy is still in early lab and early human study stages

If I boil the article down to one point, it’s this: long-term follow-up changes the conversation. Early symptom relief can look good, but what matters most is whether control lasts for 2, 5, or even 9+ years and what safety issues show up later.

Quick comparison

Approach	Main goal	Where data look strongest	What long-term results suggest	Main tradeoff
Autologous HSCT	Reset the immune system	MS, systemic sclerosis	Some patients keep remission for years; MS and SSc lead the field	Higher risk because chemotherapy is part of treatment
MSC therapy	Calm and steer immune activity	Crohn’s disease, lupus, RA	Results can last, but vary more by disease and cell source	Lower treatment burden, but less settled long-term data
Exosomes	Deliver cell signals without whole cells	Early lupus and other autoimmune research	Too early to judge durability	Still early-stage

So if you’re reading this to understand where stem cell therapy stands in 2026, the answer is simple: HSCT leads on durability, MSCs are still building their case, and banking cord and placental tissue research is growing but not routine care.

Background: How Stem Cell Therapies Are Used in Autoimmune Disease Research

Disease severity and the way the immune system behaves shape which stem cell approach researchers study: HSCT or MSCs.

Autologous HSCT in Severe Refractory Disease

With that setup in mind, HSCT is still the main research model for severe disease when the goal is an immune reset. Researchers study autologous HSCT in severe, treatment-resistant autoimmune disease, especially MS and systemic sclerosis, to reset immunity using the patient’s own stem cells after conditioning.

Recent 2026 data also point to reduced-intensity conditioning as a safer transplant approach, with strong short-term safety signals.

MSCs From Bone Marrow, Adipose Tissue, Cord Tissue, and Placenta

When a full immune reset is too risky or simply not needed, researchers shift to MSC-based approaches. MSCs don’t reset immunity. Instead, they modulate inflammation through secreted signals.

Researchers source MSCs from:

• bone marrow
• adipose tissue
• umbilical cord
• placenta

The source matters because it can change potency. Cord-derived MSCs are often favored in research because they expand more easily and are biologically younger.

In SLE, donor-derived MSCs are often preferred because a patient’s own MSCs may be less functional. And like many cell therapies, MSCs can behave differently depending on the inflammatory setting around them.

What Studies Measure in 2026

In 2026, studies are centered on durability, safety, and potency testing. In MS, key readouts include survival, disability change, and T-cell suppression assays.

That matters for a simple reason: long-term response - not just early symptom change - is what tells researchers whether a therapy has clinical meaning. That’s why the strongest long-term data right now come from HSCT first, followed by MSC-based therapies.

Long-Term Outcomes of Autologous HSCT

Multiple Sclerosis and Systemic Sclerosis: Where the Evidence Is Strongest

The longest follow-up data point to two areas where autologous HSCT appears to hold up best: multiple sclerosis (MS) and systemic sclerosis (SSc).

In selected patients, autologous HSCT is used to reset the immune system and keep remission going over time.

For MS, the long-term numbers are strong. HSCT reports NEDA rates of 66% to 93%, including 82% at 2 years in a 22-patient RRMS cohort and 92% 3-year progression-free survival in a 2026 reduced-intensity conditioning cohort. That 2026 cohort included 23 adults, with 11 patients with RRMS and 7 with PPMS. It also reported no transplant-related deaths at 3 years. On top of that, 75% of MS patients had an EDSS disability score decrease of at least 2 points within the first year.

A similar pattern shows up in systemic sclerosis. In SSc, ASTIS and SCOT found better survival and less skin thickening than monthly cyclophosphamide. A Greek cohort of 17 SSc patients followed for a median of 9.1 years reported 94.2% overall survival and a median mRSS drop from 31 to 7. Across SSc studies, 5-year progression-free survival ranges from 70% to 74%.

What Long-Term Safety Data Show

Strong results don't erase the risks of transplant. That's why the safety data matter just as much as the remission data.

Reduced-intensity conditioning, or RIC, is now used to lower toxicity, fertility risk, and organ damage while still preserving remission. A 2026 study published in Transplantation and Cellular Therapy followed 23 adult patients with autoimmune diseases treated with RIC HSCT between May 2020 and August 2025. It recorded 100% overall survival and no transplant-related deaths at 3 years.

Early complications were manageable:

• 8 cases of neutropenic fever
• 1 case of COVID pneumonia within the first 100 days

Late risks still matter. These include thyroiditis, viral reactivation such as CMV, EBV, and herpes zoster, rare secondary malignancies, and fertility loss with high-dose cyclophosphamide. That's why lifelong monitoring is still standard.

Limits of HSCT Evidence Across Other Autoimmune Diseases

Outside MS and SSc, the picture gets less steady. SLE and Crohn's disease are usually framed as clinical options rather than standard recommendations. Rheumatoid arthritis (RA) has even thinner long-term data.

Disease	5-Year Progression-Free Survival
Multiple Sclerosis	73–90% (RRMS)
Systemic Sclerosis	70–74%
Systemic Lupus Erythematosus	50–66% disease-free survival
Rheumatoid Arthritis	~18%
Crohn's Disease	~50% mucosal healing

The gap between diseases is hard to miss. So far, the strongest durability data remain in MS and SSc.

Long-Term Outcomes of MSC and Perinatal Tissue-Derived Therapies

HSCT still gets most of the attention in severe, treatment-resistant autoimmune disease. But MSC therapies are built for a different job. Instead of trying to reset the immune system, they aim to calm and steer it. And now that more studies go past the 12-month mark, we’re starting to get a clearer look at how long those effects may last.

Crohn's Disease, Lupus, and Rheumatoid Arthritis

Long-term results with MSC therapy don’t look the same across every disease. Still, the newer data give plenty of reason to pay attention.

In rheumatoid arthritis, a long-term extension study published in Stem Cell Research & Therapy in November 2025 followed 110 patients for five years. Patients treated with MSCs primed with IFN-γ had an ACR20 response rate of 89.3% at five years, compared with 44.9% for MSC monotherapy. The DAS28 remission rate was 25% in the combination group versus 2.9% in the monotherapy group. Serious adverse events stayed low, at 2.31–2.47 per 100 patient-years, and no new safety signals appeared during the full follow-up period. That shifts the discussion toward a practical point: different types of stem cells and their long-term effects may matter a lot.

For lupus nephritis, a real-world observational study at Nanjing Drum Tower Hospital followed 120 patients treated with umbilical cord-derived MSCs from 2009 to 2022. At 12 months, the cumulative renal response rate was 56.7%. Proteinuria fell from 3.2 g/24 h to 1.2 g/24 h. Daily prednisone use dropped from 20 mg to 10 mg. The relapse rate at 12 months was 8.8%.

In Crohn's disease, follow-up lasting up to four years shows sustained fistula closure and symptom improvement in refractory perianal disease. That puts more focus on perinatal tissue sources, especially as researchers look for options that can hold up over time.

Cord- and Placenta-Derived MSCs in Clinical Research

In 2026 research, umbilical cord-derived MSCs are getting more attention than bone marrow-derived MSCs. Studies report stronger immunomodulatory effects and higher proliferative capacity in clinical cohorts.

Placenta-derived MSCs are still earlier in the pipeline. In MS, the results are mixed so far. Even so, early studies show a reassuring safety profile, with only rare grade 1 anaphylactoid reactions reported. Most placental MSC use is still in early exploratory work, and the findings have not yet been confirmed in larger trials.

Durability and Safety Across MSC Approaches: A Comparison

MSC Source	Primary Disease Studied	Follow-up Length	Durability	Key Safety Findings
Bone Marrow (BM-MSCs)	RA, SLE, Crohn's	1–5 years	High in RA; sustained fistula closure in Crohn's	No increase in SAEs over 5 years
Umbilical Cord (UC-MSCs)	SLE, RA, lupus nephritis	1–6 years	56.7% renal response at 12 months; stable 5-year RA response	2.1% infusion reactions; 10.9% mild infection rate at 12 months
Placenta-Derived	MS, SLE	1 year+	Early-phase evidence; safety and feasibility confirmed	Generally safe; rare grade 1 anaphylactoid reactions

These patterns in durability and safety lead straight to the next issue: whether exosomes and other perinatal approaches can deliver the same kind of staying power.

What's Next in 2026: Exosomes, Perinatal Stem Cells, and What This Means for Families

Exosome Research as an Early Immune-Modulating Strategy

After HSCT and MSCs, research is starting to look at something smaller than whole cells: exosomes.

These tiny cell-derived particles carry active molecules and may help calm immune activity without using live cells. That’s a big part of the appeal. Instead of giving whole cells, researchers are studying whether these particles can deliver some of the same immune effects in a more controlled way.

Early lupus studies suggest exosomes may reduce inflammation. Similar work is also underway in rheumatoid arthritis, systemic sclerosis, and Sjögren's syndrome. Still, it’s important to keep expectations grounded. This area is promising, but it remains preclinical or in early clinical stages. Most autoimmune stem cell trials are still early stage, so exosome therapies are not routine care.

Why Cord Blood, Cord Tissue, and Placental Tissue Matter in Research

This same line of research is also drawing more attention to tissues collected at birth.

Cord tissue and placental tissue matter because they are important MSC sources. Researchers study them closely for immune modulation, and they are easier to expand than some other sources. Cord blood plays a different role: it provides hematopoietic stem cells tied to immune resetting research.

Americord Registry preserves cord blood, cord tissue, placental tissue, and exosomes collected at birth for future research and potential clinical use.

Conclusion: Where the Evidence Stands and Key Takeaways

For families, the takeaway is pretty simple: preservation may support future options, but it does not guarantee treatment.

Here’s where the evidence stands today:

• Autologous HSCT has the strongest long-term evidence
• MSC therapy shows promise in select autoimmune diseases
• Exosome and perinatal tissue approaches are still early-stage

For families thinking ahead, newborn stem cell banking preserves access to biological material that may matter more as the science develops.

FAQs

Who is a good candidate for autologous HSCT?

Good candidates for autologous hematopoietic stem cell transplantation (HSCT) are usually people with severe autoimmune diseases that haven’t responded to standard treatment, including conventional drugs or biologic therapies.

That said, HSCT isn’t always saved for the very end. In some diseases - especially multiple sclerosis and systemic sclerosis - doctors may look at HSCT earlier in the course of care instead of waiting until every other option has failed.

Before treatment, patients need thorough screening to check whether HSCT is a good fit and to weigh the risks. Care should also be handled by a multidisciplinary team at an accredited institution, since this type of treatment calls for close coordination across specialties.

How do MSCs differ from HSCT in autoimmune disease treatment?

HSCT is meant to reset the immune system. It uses chemotherapy to wipe out the malfunctioning immune system, then replaces it with healthy stem cells so the body can rebuild self-tolerance.

MSCs take a different path. They modulate the immune response and help repair damaged tissue. Instead of replacing the immune system, they dial down excessive immune activity and support regulatory T cells.

Can cord blood or cord tissue be used for future autoimmune therapies?

Yes. Cord blood and cord tissue are being studied for their part in future autoimmune therapies, with a lot of attention on mesenchymal stromal cells (MSCs). These cells may help regulate immune responses and support tissue repair.

Recent 2025 preclinical research found that umbilical cord-derived MSCs reduced inflammation and improved disease models of scleroderma and multiple sclerosis. Americord Registry supports this work through newborn stem cell banking.